Crispr Therapeutics (NASDAQ:CRSP) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday, BidAskClub reports.
CRSP has been the topic of a number of other reports. Goldman Sachs Group raised their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Oppenheimer raised their price objective on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, November 25th. Wells Fargo & Co reissued a “buy” rating on shares of Crispr Therapeutics in a research note on Tuesday, November 19th. ValuEngine raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. Finally, Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $69.54.
Shares of CRSP stock opened at $71.65 on Friday. The stock’s 50 day simple moving average is $49.98 and its 200 day simple moving average is $46.23. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $74.00. The company has a market capitalization of $3.96 billion, a price-to-earnings ratio of -20.83 and a beta of 3.15.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. On average, analysts forecast that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares in the company, valued at $390,000. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,118 shares of company stock worth $3,620,760. Company insiders own 21.40% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Nikko Asset Management Americas Inc. increased its position in Crispr Therapeutics by 48.4% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after buying an additional 906,006 shares during the period. ARK Investment Management LLC grew its holdings in shares of Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after purchasing an additional 701,332 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares in the last quarter. Finally, Orbimed Advisors LLC acquired a new stake in shares of Crispr Therapeutics during the 3rd quarter worth approximately $21,167,000. 49.81% of the stock is currently owned by institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.